- Veracyte to Participate in Upcoming Investor Conferences
- 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
More ▼
Key statistics
On Friday, Veracyte Inc (VCYT:NMQ) closed at 22.88, 22.94% above the 52 week low of 18.61 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.44 |
---|---|
High | 23.47 |
Low | 22.85 |
Bid | 21.53 |
Offer | 24.00 |
Previous close | 23.40 |
Average volume | 851.52k |
---|---|
Shares outstanding | 76.45m |
Free float | 75.80m |
P/E (TTM) | -- |
Market cap | 1.72bn USD |
EPS (TTM) | -0.9346 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼